Generic drug shortage in Japan: GMP noncompliance and associated quality issues.

[1]  Yasuhiro Abe,et al.  [Shortages of Prescription Drugs Due to Compliance and Quality Issues in Japan]. , 2022, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[2]  A. Lyles,et al.  National and transnational drug shortages: a quantitative descriptive study of public registers in Europe and the USA , 2022, BMC Health Services Research.

[3]  Sérgio Simões,et al.  Quality by Design (QbD) Approach in Marketing Authorization Procedures of Non-Biological Complex Drugs: A Critical Evaluation. , 2022, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  Jõao Sousa,et al.  Regulatory Science Approach in Pharmaceutical Development of Follow-On Versions of Non-Biological Complex Drug Products. , 2022, Journal of pharmaceutical sciences.

[5]  M. Barolo,et al.  A review on the modernization of pharmaceutical development and manufacturing - Trends, perspectives, and the role of mathematical modeling. , 2022, International journal of pharmaceutics.

[6]  Mark S. Daskin,et al.  Pharmaceutical supply chain reliability and effects on drug shortages , 2021, Comput. Ind. Eng..

[7]  J. Polli,et al.  Research and Education Needs for Complex Generics , 2021, Pharmaceutical Research.

[8]  Ryosuke Kuribayashi,et al.  Generic Drug Product Development in Japan: Regulatory Updates During 2014–2019 and the Future , 2021, European journal of drug metabolism and pharmacokinetics.

[9]  N. Ohmagari,et al.  Effects of the cefazolin shortage on the sales, cost, and appropriate use of other antimicrobials , 2021, BMC Health Services Research.

[10]  D. Larsson,et al.  Supply chain transparency and the availability of essential medicines , 2021, Bulletin of the World Health Organization.

[11]  A. Igarashi,et al.  Determinants of market prices for drugs under Japan’s national health insurance , 2021, Journal of Medical Economics.

[12]  S. Vogler,et al.  How to address medicines shortages: Findings from a cross-sectional study of 24 countries , 2020, Health Policy.

[13]  M. Kondoh,et al.  New Japanese Regulatory Frameworks for Post-Marketing Management of Pharmaceutical Products , 2020, Pharmaceutical Research.

[14]  Amitava Mitra,et al.  Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report. , 2020, Journal of pharmaceutical sciences.

[15]  Y. Tokuda,et al.  Critical national shortage of cefazolin in Japan: management strategies. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  P. Minghetti,et al.  New regulatory strategies to manage medicines shortages in Europe , 2020, International Journal of Pharmaceutics.

[17]  S. Miyazaki,et al.  Comparative Study of Pharmacopoeias in Japan, Europe, and the United States: Toward the Further Convergence of International Pharmacopoeial Standards. , 2019, Chemical and pharmaceutical bulletin.

[18]  B. Godman,et al.  Medicine Shortages: Gaps Between Countries and Global Perspectives , 2019, Front. Pharmacol..

[19]  A. Kesselheim,et al.  Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study , 2018, British Medical Journal.

[20]  Daigo Fukumoto,et al.  Drugs Targeted for Price Cutting in Japan: The Case of Price Revisions Based on the Divergence of Official Versus Delivery Prices , 2017, Therapeutic Innovation and Regulatory Science.

[21]  P. Minghetti,et al.  The strategic relevance of manufacturing technology: An overall quality concept to promote innovation preventing drug shortage. , 2017, International journal of pharmaceutics.

[22]  Lan Zhang,et al.  Application of quality by design in the current drug development , 2016, Asian journal of pharmaceutical sciences.

[23]  C. Yomota,et al.  Scientific and regulatory approaches to confirm quality and improve patient perceptions of generic drug products in Japan , 2016 .

[24]  Frances J. Richmond,et al.  Incentivizing Quality in the Manufacture of Pharmaceuticals: Industry Views on Quality Metrics and Ratings , 2015, Therapeutic innovation & regulatory science.

[25]  Kenichi Mikami,et al.  Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects , 2015, The AAPS Journal.

[26]  S. Simoens,et al.  Causes of drug shortages in the legal pharmaceutical framework. , 2015, Regulatory toxicology and pharmacology : RTP.

[27]  S. Dill,et al.  Drug shortages in developed countries—reasons, therapeutic consequences, and handling , 2014, European Journal of Clinical Pharmacology.

[28]  Matthew Howard,et al.  Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm , 2014, AAPS PharmSciTech.

[29]  N. Katori.  [Accession to the PIC/S and pharmaceutical quality system in Japan]. , 2014, Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo hokoku = Bulletin of National Institute of Health Sciences.

[30]  Y. Imanaka,et al.  Improving the assessment of prescribing: use of a ‘substitution index’ , 2013, Journal of Health Services Research and Policy.

[31]  Chris Holloway,et al.  Scientific considerations for complex drugs in light of established and emerging regulatory guidance , 2012, Annals of the New York Academy of Sciences.

[32]  Yukio Hiyama.  [Pharmaceutical product quality control and good manufacturing practices]. , 2010, Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo hokoku = Bulletin of National Institute of Health Sciences.

[33]  Andre Raw,et al.  Quality by Design: Concepts for ANDAs , 2008, The AAPS Journal.

[34]  Robert A. Lionberger,et al.  FDA Critical Path Initiatives: Opportunities for Generic Drug Development , 2008, The AAPS Journal.